Moderna has even shot out in entrance, approaching US and UK authorities to make use of their vaccine for emergent remedies.
Whereas Trinidad and Tobago stands firmly as a part of the COVAX facility, which can be sure that the nation is given the best-suited vaccine for our circumstances, native consultants are inspecting the variations among the many vaccines prone to come our means.
Professor Christine Carrington, who works in molecular genetics and virology on the College of the West Indies, defined that whereas the Moderna and Pfizer choices have related traits, the Astra Zeneca vaccine has key variations.
These vaccines don’t include the entire COVID-19 virus. As an alternative, they assist to use its genetic materials and present a forcefield to guard the affected person from the virus.
“You can use just a small piece of the genetic material from the disease-causing virus; not the whole genome of the virus, just the part with the protein that will trigger the immune response. When this genetic material is delivered into the cell, the cell will produce the protein and the immune response is triggered,” defined Carrington.
The mRNA vaccines don’t alter different genetic materials or impression the physique’s capabilities. It additionally by no means enters the nucleus of the cells within the physique and subsequently, doesn’t replicate.
Whereas it’s a brand new wave within the expertise for vaccine creation, most consultants agree that these vaccines will likely be protected regardless of the tempo in growth.
AstraZeneca, alternatively, is a viral vector vaccine.
It additionally doesn’t trigger the illness to manifest, however it does enter the nucleus of the physique’s cells.
AstraZeneca’s providing can also be cheaper and simpler to retailer. It may be saved in a fridge between 4 to eight levels Celsius.
The mRNA vaccines are pricier, however they’re fast and comparatively straightforward to develop.
In response to Professor Carrington, a few of these particulars are nonetheless topic to vary, however it received’t be lengthy earlier than no less than one of them hits the market.
“None of these candidate vaccines has completed their phase three trials so we have to wait for that to be completed to get the full data but it’s going to happen very soon, I expect. The results are, so far, immensely encouraging since there have been no significant side effects in the tens of thousands of people in the trials and they do appear to be giving good protection,” she stated.
Trinidad and Tobago’s authorities has already begun placing measures in place to facilitate the arrival of a vaccine, with healthcare and entrance line staff being first on the record for vaccination.